GSK Announces $30 Billion Investment in U.S. R&D and Infrastructure Over Five Years

On September 17, global biopharmaceutical company GSK issued a statement announcing plans to invest $30 billion in the United States over the next five years for research and development as well as supply chain infrastructure construction. GSK stated that $1.2 billion of this will be used to invest in advanced manufacturing facilities, artificial intelligence, and cutting-edge digital technologies, with the aim of building a new generation of biopharmaceutical factories and laboratories in the United States.